Nivolumab B-DESC
administration O
will O
be O
delayed O
in O
case O
of O
any O
AE O
, O
laboratory O
abnormality O
or O
intercurrent O
illness O
which O
, O
in O
the O
judgment O
of O
the O
investigator O
, O
warrants O
delaying O
the O
dose O
of O
study O
medication O
. O

Subjects O
may O
continue O
to O
receive O
treatment O
beyond O
confirmed O
progression O
in O
the O
absence O
of O
clinically O
significant O
deterioration O
and O
if O
investigators O
expect O
continual O
benefit O
from O
the O
treatment O
. O
For O
statistical O
analyses O
, O
these O
subjects O
will O
be O
considered O
to O
have O
investigator O
- O
assessed O
progressive O
disease O
at O
the O
time O
of O
the O
initial O
progression O
event O
. O

Radiotherapy B-DESC
planning O
will O
be O
based O
on O
computed O
tomography O
( O
CT O
) O
images O
with O
minimal O
5 O
mm O
slices O
. O
For O
robust O
and O
reproducible O
patient O
positioning O
during O
both O
planning O
and O
treatment O
, O
all O
positioning O
aids O
( O
e.g. O
masks O
, O
cushions O
, O
vacuum O
beds O
) O
are O
allowed O
. O

For O
irradiation O
, O
tumor O
lesions O
in O
all O
non O
- O
cerebral O
/ O
nonpulmonary O
locations O
can O
be O
included O
if O
radiotherapy B-DESC
is O
indicated O
and O
prescribed O
according O
to O
common O
good O
clinical O
practice O
( O
e.g. O
bone O
, O
soft O
tissue O
, O
lymph O
nodes O
) O
. O
Internal O
organ O
metastases O
( O
such O
as O
in O
liver O
, O
pancreas O
, O
adrenal O
glands O
) O
or O
brain O
metastases O
should O
not O
be O
irradiated O
. O
Patients O
with O
thoracic O
lesions O
( O
e.g. O
thoracic O
spine O
, O
chest O
wall O
) O
or O
mediastinal O
lymph O
nodes O
will O
be O
included O
if O
the O
planning O
target O
volume O
( O
PTV O
) O
for O
irradiation O
does O
not O
directly O
intersect O
with O
the O
contoured O
lungs O
. O

Gross O
tumor O
volumes O
( O
GTV O
) O
are O
contoured O
on O
the O
planning O
CT O
, O
considering O
additional O
co O
- O
registered O
imaging O
techniques O
such O
as O
magnetic O
resonance O
imaging O
( O
MRI O
) O
or O
positron O
emission O
tomography O
( O
PET O
) O
, O
if O
available O
. O
Derived O
from O
the O
GTV O
, O
clinical O
( O
CTV O
) O
and O
planning O
target O
volumes O
( O
PTV O
) O
are O
created O
using O
common O
institutional O
margins O
to O
confidently O
cover O
radiation O
targets O
and O
simultaneously O
spare O
organs O
at O
risk O
( O
OAR O
) O
. O
Contouring O
of O
relevant O
OAR O
is O
only O
necessary O
in O
cases O
of O
close O
vicinity O
or O
anticipated O
critical O
radiation O
exposure O
. O
In O
case O
of O
thoracic O
target O
volumes O
, O
both O
lungs O
will O
be O
contoured O
to O
monitor O
lung O
dose O
exposure O
, O
which O
is O
required O
to O
be O
as O
low O
as O
reasonably O
achievable O
. O
In O
cases O
of O
subtotal O
lung O
registration O
, O
the O
OAR O
" O
both O
partial O
lungs O
" O
will O
be O
generated O
. O

Radiation O
delivery O
must O
be O
planned O
3D O
- O
conformally O
and O
CT O
- O
based O
with O
either O
photons O
or O
electrons O
including O
step O
- O
and O
- O
shoot O
/ O
helical O
/ O
volumetric O
intensity O
- O
modulated O
, O
stereotactic O
or O
conventional O
techniques O
using O
linear O
accelerators O
. O
Radiotherapy B-DESC
is O
delivered B-DOSAGE
on I-DOSAGE
workdays I-DOSAGE
in I-DOSAGE
5 I-DOSAGE
single I-DOSAGE
fractions I-DOSAGE
of I-DOSAGE
4 I-DOSAGE
Gy I-DOSAGE
up I-DOSAGE
to I-DOSAGE
a I-DOSAGE
total I-DOSAGE
dose I-DOSAGE
of I-DOSAGE
20 I-DOSAGE
Gy I-DOSAGE
. O
Therefore O
, O
radiotherapy B-DESC
is O
expected O
to O
last O
no O
longer O
than O
2 O
weeks O
. O
Dose O
specification O
follows O
the O
requirements O
of O
the O
reports O
50 O
, O
62 O
, O
and O
83 O
of O
the O
International O
Commission O
of O
Radiation O
Units O
and O
Measurements O
. O

Adequate O
patient O
positioning O
and O
correct O
isocenter O
localisation O
are O
verified O
radiologically O
making O
use O
of O
either O
kV O
/ O
MV O
- O
cone O
/ O
fan O
- O
beam O
- O
CTs O
or O
conventional O
Xray O
- O
documentation O
of O
either O
isocenter O
or O
radiation O
fields O
. O
If O
positioning O
corrections O
are O
necessary O
, O
they O
must O
be O
documented O
in O
the O
radiotherapy B-DESC
protocol O
. O

Tissue O
collection O
For O
each O
patient O
a O
formalin O
- O
fixed O
, O
paraffin O
- O
embedded O
( O
FFPE O
) O
tumor O
tissue O
block O
( O
archival O
or O
recent O
) O
or O
a O
minimum O
of O
15 O
unstained O
slides O
of O
tumor O
sample O
( O
2 O
- O
3 O
μm O
sections O
; O
slices O
must O
be O
recent O
and O
collected O
on O
slides O
provided O
by O
the O
sponsor O
) O
must O
be O
available O
for O
biomarker O
( O
PD O
- O
L1 O
) O
evaluation O
as O
stated O
in O
the O
inclusion O
criteria O
. O
Biopsy O
should O
be O
excisional O
, O
incisional O
or O
core O
- O
needle O
. O
Fine O
- O
needle O
aspiration O
is O
insufficient O
. O
Tumor O
PD O
- O
L1 O
assessment O
for O
retrospective O
sub O
- O
group O
analysis O
will O
be O
performed O
centrally O
according O
to O
institutional O
standards O
using O
the O
PD O
- O
L1 O
IHC O
28 O
- O
8 O
pharmDx O
assay O
. O

It O
will O
be O
at O
the O
discretion O
of O
the O
investigator O
to O
determine O
whether O
a O
re O
- O
biopsy O
of O
a O
patient O
is O
required O
. O
The O
decision O
to O
re O
- O
biopsy O
shall O
be O
based O
on O
clinical O
judgment O
and O
necessity O
and O
should O
follow O
local O
guidelines O
and O
standards O
. O
If O
a O
recent O
biopsy O
has O
been O
collected O
and O
submitted O
, O
submission O
of O
archival O
tissue O
, O
if O
available O
, O
is O
still O
highly O
encouraged O
. O
In O
cases O
where O
retrospective O
haematoxylin O
and O
eosin O
staining O
by O
the O
central O
lab O
determines O
insufficient O
amounts O
of O
tumor O
tissue O
for O
the O
biomarker O
analyses O
, O
additional O
archived O
tissue O
may O
be O
requested O
by O
the O
sponsor O
, O
if O
available O
. O
If O
a O
re O
- O
biopsy O
after O
progression O
under O
study O
treatment O
is O
performed O
, O
submission O
of O
this O
tumor O
material O
is O
highly O
valued O
. O

Routine O
haematological O
analysis O
of O
red O
and O
white O
blood O
cells O
and O
platelets O
are O
part O
of O
the O
scheduled O
patient O
assessments O
under O
therapy O
and O
are O
not O
a O
specific O
part O
of O
the O
exploratory O
biomarker O
program O
. O
However O
, O
their O
results O
are O
mandatory O
baseline O
information O
as O
absolute O
cell O
counts O
for O
further O
investigations O
. O

Blood O
samples O
are O
planned O
to O
be O
taken O
in O
the O
context O
of O
study O
inclusion O
and O
before O
any O
therapeutic O
intervention O
, O
and O
serve O
as O
baseline O
controls O
. O
Furthermore O
, O
second O
blood O
samples O
are O
collected O
in O
group B-DESC
A I-DESC
on O
cycle O
1 O
, O
day O
8 O
( O
visit O
2 O
) O
after O
completion O
of O
radiotherapy B-DESC
to O
assess O
early O
radiogenic O
immune O
response O
in O
combination O
with O
nivolumab B-DESC
. O
The O
second O
blood O
sample O
in O
group B-DESC
B I-DESC
is O
also O
collected O
on O
cycle O
1 O
, O
day O
8 O
( O
visit O
2 O
) O
to O
assess O
early O
nivolumab B-DESC
- O
related O
immune O
response O
without O
radiotherapy B-DESC
. O
A O
third O
blood O
sample O
will O
be O
taken O
for O
both O
groups O
on O
cycle O
3 O
, O
day O
1 O
( O
visit O
4 O
) O
, O
when O
radiotherapy B-DESC
is O
completed O
in O
group B-DESC
A I-DESC
and O
when O
all O
patients O
( O
groups B-DESC
A I-DESC
and O
B B-DESC
) O
have O
received O
two O
doses O
of O
nivolumab B-DESC
. O
A O
fourth O
and O
final O
blood O
sample O
will O
be O
collected O
for O
both O
groups O
either O
on O
cycle O
7 O
, O
day O
1 O
or O
upon O
end O
of O
treatment O
, O
whichever O
occurs O
first O
. O

-PFS B-METRIC
-PFS B-METRIC
and O
ORR O
using O
assessment O
according O
to O
irRECIST O
-OS O
-1-year O
OS O
rate O
-Descriptive O
sub O
- O
group O
analyses O
of O
efficacy O
in O
relation O
to O
PD O
- O
L1 O
expression O
levels O
( O
e.g. O
cut O
- O
off O
1 O
, O
5 O
, O
10 O
% O
) O
-Treatment O
emergent O
adverse O
events O
according O
to O
common O
terminology O
criteria O
for O
adverse O
events O
( O
CTCAE O
) O
version O
4.03 O
-Frequency O
of O
abnormal O
laboratory O
parameters O
-Quality O
of O
Life O
[ O
FACT O
- O
L O
, O
validated O
in O
[ O
21 O
] O
Exploratory O
endpoints O
Radiation O
- O
induced O
tumor O
- O
specific O
immune O
effects O
can O
explain O
events O
of O
tumor O
regression O
upon O
radiation O
treatment O
both O
within O
and O
beyond O
the O
irradiated O
fields O
and O
the O
immune O
system O
can O
be O
further O
stimulated O
by O
administration O
of O
a O
PD-1 O
blocking O
antibody O
such O
as O
nivolumab B-DESC
. O
The O
translational O
research O
accompanying O
this O
trial O
aims O
to O
elucidate O
the O
synergistic O
, O
immunostimulatory O
effects O
of O
radiotherapy O
and O
checkpoint O
inhibition O
that O
underlie O
these O
observations O
by O
covering O
the O
following O
aspects O
. O

Exploratory O
analysis O
on O
radiation O
planning O
and O
dose O
administration O
Exploratory O
analysis O
on O
radiation O
planning O
and O
dose O
administration O
will O
help O
to O
substantiate O
the O
phenomenon O
of O
radiation O
- O
induced O
abscopal O
effects O
. O
It O
will O
improve O
the O
option O
of O
radiation O
triggered O
systemic O
response O
through O
identification O
and O
possible O
prediction O
of O
both O
eligible O
targets O
for O
irradiation O
and O
probable O
lesion O
of O
abscopal O
response O
. O
To O
this O
end O
, O
both O
the O
location O
and O
composition O
of O
radiation O
targets O
and O
the O
anatomical O
profile O
of O
abscopally O
responding O
lesion O
must O
be O
carefully O
studied O
. O

- O
Exploratory O
analysis O
on O
tissue O
samples O
Tumor O
PD O
- O
L1 O
assessments O
will O
be O
performed O
as O
part O
of O
the O
clinical O
study O
. O
The O
results O
will O
be O
used O
both O
retrospectively O
for O
patient O
sub O
- O
grouping O
and O
within O
the O
biomarker O
program O
for O
correlation O
analysis O
. O
The O
PD O
- O
L1 O
IHC O
28 O
- O
8 O
pharmDx O
assay O
will O
be O
used O
. O
In O
addition O
, O
the O
immune O
infiltrate O
associated O
with O
the O
tumor O
will O
be O
analyzed O
to O
identity O
different O
subsets O
of O
immune O
cells O
. O
To O
this O
end O
, O
tissue O
slides O
will O
be O
subjected O
to O
a O
panel O
of O
IHC O
markers O
capable O
of O
identifying O
various O
types O
of O
immune O
cells O
. O
Depending O
on O
the O
availability O
of O
tumor O
material O
, O
tissue O
samples O
will O
also O
be O
analyzed O
with O
respect O
to O
microsatellite O
instability O
. O

Exploratory O
analysis O
on O
blood O
samples O
Blood O
samples O
that O
are O
collected O
at O
different O
time O
points O
will O
be O
used O
to O
characterize O
the O
immune O
response O
and O
investigate O
biological O
processes O
before O
, O
during O
and O
after O
the O
administration O
of O
the O
treatment O
. O
Briefly O
, O
phenotypic O
fluorescence O
activated O
cell O
sorter O
( O
FACS O
) O
analysis O
will O
be O
used O
to O
analyze O
whole O
blood O
samples O
with O
respect O
to O
the O
changes O
in O
the O
T O
- O
cell O
composition O
. O
Furthermore O
, O
specific O
T O
- O
cell O
responses O
to O
a O
panel O
of O
putative O
lung O
cancer O
- O
associated O
antigens O
will O
be O
measured O
by O
IFN O
- O
γ O
enzyme O
linked O
immunospot O
technique O
using O
frozen O
peripheral O
blood O
mononuclear O
cells O
. O
T O
- O
cell O
receptor O
sequencing O
will O
be O
performed O
for O
2 O
visits O
per O
patient O
( O
baseline O
and O
end O
of O
study O
time O
point O
) O
, O
in O
order O
to O
elucidate O
whether O
and O
, O
if O
so O
, O
which O
of O
the O
T O
- O
cell O
clones O
will O
be O
expanded O
during O
treatment O
. O
Abundances O
of O
immunostimulatory O
cytokines O
will O
be O
quantified O
by O
measuring O
serum O
cytokines O
. O
Finally O
, O
changes O
in O
lymphocyte O
gene O
signature O
arising O
from O
the O
synergistic O
treatment O
of O
patients O
with O
radiotherapy B-DESC
and O
nivolumab B-DESC
will O
be O
monitored O
by O
mRNA O
expression O
profiling O
using O
mRNA O
isolated O
from O
whole O
blood O
and O
using O
the O
human O
HT-12 O
v4 O
Expression O
Bead O
- O
Chip O
Kit O
. O

The O
primary O
endpoint O
will O
be O
the O
ORR O
according O
to O
RECIST O
criteria O
1.1 O
. O
Based O
on O
the O
results O
from O
the O
Checkmate O
057 O
trial O
( O
ClinicalTrials.gov O
Identifier O
: O
NCT01673867 O
; O
[ O
5 O
] O
) O
, O
the O
ORR O
in O
group O
B O
is O
assumed O
to O
be O
19 O
% O
. O
Moreover O
, O
in O
the O
population O
with O
high O
PD O
- O
L1 O
expression O
( O
PD O
- O
L1 O
> O
10 O
% O
) O
an O
ORR O
of O
37 O
% O
was O
observed O
[ O
5 O
] O
. O
It O
is O
hypothesized O
that O
by O
combining O
nivolumab B-DESC
and O
radiotherapy B-DESC
an O
ORR O
of O
35 O
% O
can O
be O
achieved O
in O
both O
PD O
- O
L1-negative O
and O
-positive O
patients O
. O

The O
study O
requires O
n O
= O
50 O
subjects O
( O
in O
group B-DESC
A I-DESC
) O
to O
detect O
whether O
the O
responding O
proportion O
( O
ORR O
) O
is O
higher O
than O
19 O
% O
by O
applying O
a O
binomial O
test O
at O
a O
one O
- O
sided O
significance O
level O
of O
0.05 O
with O
a O
probability O
of O
1-beta O
= O
0.8 O
, O
assuming O
an O
actual O
response O
rate O
of O
35 O
% O
. O

Due O
to O
the O
fact O
that O
a O
retrospective O
PD O
- O
L1 O
analysis O
will O
be O
crucial O
to O
reach O
the O
study O
objectives O
, O
the O
PD O
- O
L1 O
status O
should O
be O
available O
for O
at O
least O
50 O
patients O
per O
treatment O
group O
. O
Practical O
experiences O
indicate O
that O
at O
a O
rate O
of O
20 O
- O
30 O
% O
tumor O
tissue O
samples O
do O
not O
contain O
sufficient O
material O
for O
a O
PD O
- O
L1 O
IHC O
assessment O
. O
By O
taking O
this O
and O
also O
potential O
patient O
dropouts O
into O
account O
, O
the O
total O
number O
of O
patients O
enrolled O
will O
be O
n O
= O
65 O
per O
group O
to O
ascertain O
the O
required O
sample O
number O
for O
the O
PD O
- O
L1 O
sub O
- O
group O
analysis O
and O
to O
achieve O
a O
sufficient O
statistical O
power O
for O
the O
primary O
analysis O
in O
case O
of O
patient O
dropouts O
. O

Statistical O
analysis O
is O
based O
on O
the O
International O
Conference O
on O
Harmonization O
Guidelines O
" O
Structure O
and O
Content O
of O
Clinical O
Study O
Reports O
" O
and O
" O
Statistical O
Principles O
for O
Clinical O
Trials O
" O
. O
The O
primary O
analysis O
set O
for O
all O
efficacy O
outcomes O
will O
be O
the O
intention O
- O
to O
- O
treat O
( O
ITT O
) O
population O
, O
while O
the O
per O
- O
protocol O
( O
PP O
) O
population O
will O
be O
used O
for O
sensitivity O
analyses O
. O

The O
primary O
endpoint O
ORR O
will O
be O
evaluated O
by O
reporting O
absolute O
and O
relative O
frequencies O
for O
both O
treatment O
groups O
. O
For O
group B-DESC
A I-DESC
, O
a O
binomial O
test O
will O
be O
conducted O
at O
a O
one O
- O
sided O
significance O
level O
of O
α O
= O
0.05 O
in O
order O
to O
assess O
if O
the O
ORR O
exceeds O
19 O
% O
. O
Furthermore O
, O
one O
- O
sided O
95%-confidence O
intervals O
will O
be O
calculated O
for O
the O
ORR O
in O
both O
groups O
. O

For O
the O
secondary O
time O
- O
to O
- O
event O
outcomes O
OS O
and O
PFS B-METRIC
, O
median O
survival O
times O
and O
1-year O
rates O
will O
be O
given O
with O
95 O
% O
confidence O
intervals O
and O
Kaplan O
- O
Meier O
curves O
will O
be O
calculated O
for O
both O
treatment O
groups O
. O

Descriptive O
sub O
- O
group O
analyses O
with O
regard O
to O
PD O
- O
L1 O
status O
will O
be O
conducted O
assessing O
the O
primary O
and O
secondary O
outcomes O
separately O
for O
the O
patient O
strata O
PD O
- O
L1 O
high O
/ O
low O
( O
e.g. O
cutoffs O
1 O
, O
5 O
, O
and O
10 O
% O
) O
by O
reporting O
the O
same O
statistical O
measures O
as O
described O
before O
for O
both O
treatment O
groups O
. O
Safety O
analysis O
will O
be O
done O
for O
all O
patients O
who O
received O
at O
least O
one O
dose O
of O
study O
medication O
and O
according O
to O
the O
treatment O
actually O
received O
. O
It O
includes O
a O
tabulation O
of O
relative O
and O
absolute O
frequencies O
for O
adverse O
and O
serious O
adverse O
events O
. O
After O
25 O
patients O
have O
been O
treated O
in O
group B-DESC
A I-DESC
, O
a O
descriptive O
safety O
report O
will O
be O
generated O
and O
evaluated O
by O
the O
Data O
Safety O
Monitoring O
Board O
. O